BALA CYNWYD, Pa., July 3, 2012 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of Amylin
Pharmaceuticals, Inc. ("Amylin" or the "Company") (Nasdaq
- AMLN) relating to the proposed acquisition by Bristol-Myers
Squibb Company ("Bristol-Myers").
Under the terms of the transaction, Amylin shareholders will
receive only $31.00 in cash for each
of Amylin stock they own. The investigation concerns possible
breaches of fiduciary duty and other violations of state law by the
Board of Directors of Amylin for not acting in the Company's
shareholders' best interests in connection with the sale process to
Bristol-Myers. The Board of Directors may have failed to adequately
shop the Company and may have undervalued Amylin resulting in harm
to the Amylin shareholders. For example, an analyst has
placed a $32.00 price target on
Amylin stock.
If you own shares of Amylin stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L.
Brodsky, Esquire or Evan J. Smith,
Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by
e-mail at investorrelations@brodsky-smith.com, visiting
http://brodsky-smith.com/444-amln-amylin-pharmaceuticals-inc.html,
or by calling toll free 877-LEGAL-90.
SOURCE Brodsky & Smith, LLC